{"analyses":[{"ciLowerLimit":"2.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.43","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Odds Ratio (OR)","paramValue":"4.62","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.9","upperLimit":"70.9","value":"58.3"},{"groupId":"OG001","lowerLimit":"14.1","upperLimit":"37.8","value":"24.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who achieved a best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) using the modified International Myeloma Working Group (IMWG) criteria described as follows, as per investigator's assessment\n\n* CR: Negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and \\< 5% plasma cells in bone marrow\n* sCR: CR, as defined above, plus the following: Normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\n* VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>= 90% reduction in serum M-protein level plus urine M-protein level \\< 100 mg per 24 hour\n* PR: \\>= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hour.","dispersionType":"95% Confidence Interval","groups":[{"description":"Elotuzumab + Pomalidomide + Dexamethasone","id":"OG000","title":"E-Pd Cohort"},{"description":"Pomalidomide + Dexamethasone","id":"OG001","title":"Pd Cohort"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From first dose to disease progression (up to approximately 21 months)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percent of participants"}